Literature DB >> 10585451

Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver.

A R Mensenkamp1, M C Jong, H van Goor, M J van Luyn, V Bloks, R Havinga, P J Voshol, M H Hofker, K W van Dijk, L M Havekes, F Kuipers.   

Abstract

ApoE-deficient mice on low fat diet show hepatic triglyceride accumulation and a reduced very low density lipoprotein (VLDL) triglyceride production rate. To establish the role of apoE in the regulation of hepatic VLDL production, the human APOE3 gene was introduced into apoE-deficient mice by cross-breeding with APOE3 transgenics (APOE3/apoe-/- mice) or by adenoviral transduction. APOE3 was expressed in the liver and, to a lesser extent, in brain, spleen, and lung of transgenic APOE3/apoe-/- mice similar to endogenous apoe. Plasma cholesterol levels in APOE/apoe-/- mice (3.4 +/- 0.5 mM) were reduced when compared with apoe-/- mice (12.6 +/- 1.4 mM) but still elevated when compared with wild type control values (1.9 +/- 0.1 mM). Hepatic triglyceride accumulation in apoE-deficient mice was completely reversed by introduction of the APOE3 transgene. The in vivo hepatic VLDL-triglyceride production rate was reduced to 36% of control values in apoE-deficient mice but normalized in APOE3/apoe-/- mice. Hepatic secretion of apoB was not affected in either of the strains. Secretion of (3)H-labeled triglycerides synthesized from [(3)H]glycerol by cultured hepatocytes from apoE-deficient mice was four times lower than by APOE3/apoe-/- or control hepatocytes. The average size of secreted VLDL particles produced by cultured apoE-deficient hepatocytes was significantly reduced when compared with those of APOE3/apoe-/- and wild type mice. Hepatic expression of human APOE3 cDNA via adenovirus-mediated gene transfer in apoE-deficient mice resulted in a reduction of plasma cholesterol depending on plasma apoE3 levels. The in vivo VLDL-triglyceride production rate in these mice was increased up to 500% compared with LacZ-injected controls and correlated with the amount of apoE3 per particle. These findings indicate a regulatory role of apoE in hepatic VLDL-triglyceride secretion, independent from its role in lipoprotein clearance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10585451     DOI: 10.1074/jbc.274.50.35711

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

Review 1.  Postprandial lipemia and cardiovascular disease.

Authors:  Dianne Hyson; John C Rutledge; Lars Berglund
Journal:  Curr Atheroscler Rep       Date:  2003-11       Impact factor: 5.113

2.  Activation of hepatic CREBH and Insig signaling in the anti-hypertriglyceridemic mechanism of R-α-lipoic acid.

Authors:  Xuedong Tong; Patricia Christian; Miaoyun Zhao; Hai Wang; Regis Moreau; Qiaozhu Su
Journal:  J Nutr Biochem       Date:  2015-05-07       Impact factor: 6.048

3.  Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome.

Authors:  Andreas Merz; Gang Long; Marie-Sophie Hiet; Britta Brügger; Petr Chlanda; Patrice Andre; Felix Wieland; Jacomine Krijnse-Locker; Ralf Bartenschlager
Journal:  J Biol Chem       Date:  2010-11-05       Impact factor: 5.157

4.  MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis.

Authors:  Wei-Chih Tsai; Sheng-Da Hsu; Chu-Sui Hsu; Tsung-Ching Lai; Shu-Jen Chen; Roger Shen; Yi Huang; Hua-Chien Chen; Chien-Hsin Lee; Ting-Fen Tsai; Ming-Ta Hsu; Jaw-Ching Wu; Hsien-Da Huang; Ming-Shi Shiao; Michael Hsiao; Ann-Ping Tsou
Journal:  J Clin Invest       Date:  2012-07-23       Impact factor: 14.808

5.  Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes.

Authors:  Anne Hiukka; Jamila Fruchart-Najib; Eeva Leinonen; Hannele Hilden; Jean-Charles Fruchart; Marja-Riitta Taskinen
Journal:  Diabetologia       Date:  2005-04-30       Impact factor: 10.122

6.  Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome.

Authors:  Esther M M Ooi; Theodore W K Ng; Gerald F Watts; Dick C Chan; P Hugh R Barrett
Journal:  J Lipid Res       Date:  2012-08-28       Impact factor: 5.922

7.  Hepatobiliary cholesterol transport is not impaired in Abca1-null mice lacking HDL.

Authors:  A K Groen; V W Bloks; R H Bandsma; R Ottenhoff; G Chimini; F Kuipers
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

8.  Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion.

Authors:  Meenakshi Sundaram; Zemin Yao
Journal:  Nutr Metab (Lond)       Date:  2010-04-27       Impact factor: 4.169

9.  ApoE derived from adipose tissue does not suppress atherosclerosis or correct hyperlipidemia in apoE knockout mice.

Authors:  Zhi H Huang; Catherine A Reardon; Papasani V Subbaiah; Godfrey S Getz; Theodore Mazzone
Journal:  J Lipid Res       Date:  2012-10-15       Impact factor: 5.922

10.  Defective lipid delivery modulates glucose tolerance and metabolic response to diet in apolipoprotein E-deficient mice.

Authors:  Susanna M Hofmann; Diego Perez-Tilve; Todd M Greer; Beth A Coburn; Erin Grant; Joshua E Basford; Matthias H Tschöp; David Y Hui
Journal:  Diabetes       Date:  2007-10-03       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.